Tandem Diabetes (TNDM) Misses Q1 EPS by 16c

Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.23), $0.16 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $175.9 million versus the consensus estimate of $168.43 million.

GUIDANCE:

Tandem Diabetes sees FY2022 revenue of $850-865 million, versus the consensus of $846.5 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• H.B. Fuller board rejects Ancora's $1.1B-$1.2B BAS unit bid